HENDERSON, Nev.–(BUSINESS WIRE)–Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement andHENDERSON, Nev.–(BUSINESS WIRE)–Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and

Paysign, Inc. to Present at the Oppenheimer 11th Annual Emerging Growth Conference

HENDERSON, Nev.–(BUSINESS WIRE)–Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced it will be presenting at the Oppenheimer 11th Annual Emerging Growth Conference to be held February 3-4, 2026, through a virtual format.

The focus of the virtual conference is to feature one-on-one and small group meetings with emerging companies in technology, industrial growth and consumer sectors. Paysign’s Chief Financial Officer, Jeff Baker, will host one-on-one meetings on Tuesday, February 3.

Investors interested in registering may contact their Oppenheimer representative.

About Paysign

Paysign, Inc. (NASDAQ: PAYS) operates at the intersection of fintech and healthcare, integrating advanced payment processing and program management with tailored technologies for the plasma, pharmaceutical and life sciences industries. Their breakthrough patient affordability solutions ensure patients receive the financial assistance they need to adhere to prescribed therapies by mitigating the effects of copay accumulators and maximizers. Paysign specializes in blood and plasma donor compensation programs, as well as comprehensive engagement and management platforms optimized for life sciences. Paysign’s proprietary processing architecture supports physical, virtual, mobile and bank-based payments with real-time transaction intelligence, enabling efficient, compliant and scalable program delivery. Through advanced reporting, analytics and in-house 24/7 bilingual customer support, Paysign delivers measurable value, exceptional service and a superior experience for donors, patients, healthcare providers, pharmaceutical manufacturers and program sponsors across their growing fintech healthcare ecosystem. The company is committed to improving efficiencies, reducing costs, streamlining communications, increasing program performance and providing actionable insights to those they serve.

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. Paysign undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

Contacts

Investor Relations
[email protected]
888.522.4853

paysign.com/investors

Media Relations
Alicia Ches

888.522.4850

[email protected]

Market Opportunity
WorldAssets Logo
WorldAssets Price(INC)
$0.7089
$0.7089$0.7089
+1.43%
USD
WorldAssets (INC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Why Smart Whales Abandon Cardano And Solana, Choosing Pepeto Presale For 100x Potential

Why Smart Whales Abandon Cardano And Solana, Choosing Pepeto Presale For 100x Potential

But a new player is emerging quickly: Pepeto (PEPETO), still in presale at just $0.000000153, already garnering over $6.7 million. […] The post Why Smart Whales Abandon Cardano And Solana, Choosing Pepeto Presale For 100x Potential appeared first on Coindoo.
Share
Coindoo2025/09/20 01:35
Trump supporter and Palantir co-founder Joe Lonsdale opposes Trump's pardon of Changpeng Zhao

Trump supporter and Palantir co-founder Joe Lonsdale opposes Trump's pardon of Changpeng Zhao

PANews reported on October 24th that according to AXIOS, Joe Lonsdale, a wealthy supporter of US President Trump and co-founder of Palantir, has publicly opposed yesterday's pardon of cryptocurrency billionaire Changpeng Zhao. Zhao was previously convicted of anti-money laundering violations and sentenced to four months in prison. In a post on the X platform, he stated: "I support President Trump. This administration could have been the most outstanding I have ever seen—if it weren't for these pardons. Judged by objective standards, these pardons are completely unjustified. The President has been seriously misled about this matter, and it creates the impression that a major financial fraud is flourishing around him." This criticism, coming from within Trump's political allies, highlights potential doubts about the Trump family's business practices in the cryptocurrency sector.
Share
PANews2025/10/24 17:25
Win Big! No Deposit Welcome Bonuses Guide

Win Big! No Deposit Welcome Bonuses Guide

Cryptsy - Latest Cryptocurrency News and Predictions Cryptsy - Latest Cryptocurrency News and Predictions - Experts in Crypto Casinos Imagine stepping into the
Share
Cryptsy2026/02/02 10:20